DNATRIX, INC.;BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
发明人:
Frank TUFARO,Charles CONRAD,Juan FUEYO-MARGARETO,Frederick LANG, JR.,Candelaria GOMEZ-MANZANO,W.K. Alfred YUNG,Amy HEIMBERGER
申请号：
US16293624
公开号：
US20190269744A1
申请日:
2019.03.05
申请国别(地区):
US
年份:
2019
代理人:
摘要：
The invention disclosed herein describes biomarkers useful for prognosis, selection and monitoring of oncolytic virus therapy for patients with various types of cancer. In particular, the present invention provides identification of proteins whose expression patterns are strongly predictive of the outcome of oncolytic virus therapy in a patient with cancer. The present invention provides a method for identifying and selecting cancer patients who are likely to be non-responsive to onocolytic virus therapy. These patients can be co-administered an agent that stimulates a cell-mediated immune response in the patient with the oncolytic virus or can be administered a therapy other than oncolytic virus therapy.
